Brief: MaaT Pharma Q1 Revenue At EUR 0.7 Million
May 9 (Reuters) - Maat Pharma SA MAAT.PA :
* MAAT PHARMA ANNOUNCES CASH AND REVENUES FOR Q1 OF 2023
* AS OF MARCH 31, 2023, CASH AND CASH EQUIVALENTS WERE EUR
40.7
MILLION
* REVENUES OF EUR 0.7 MILLION IN Q1 2023
* SIGNIFICANT GROWTH REFLECTS INCREASING DEMAND, OVER
PERIOD, FOR
USE OF MAAT013 UNDER EARLY ACCESS PROGRAM IN EUROPE
Source text for Eikon: ID:nBw6rl84ra
Further company coverage: MAAT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Maat Pharma SA
See all newsBrief: MaaT Pharma Says FDA Indicates No Additional Nonclinical Studies Required For MaaT034 Safety
France's MaaT Pharma H1 operating loss widens on higher R&D costs
Brief: MaaT Pharma SA Receives 'Negative Trend' Opinion For Upcoming June CHMP Vote For MaaT013 (Xervyteg)
France's MaaT Pharma 2025 revenue rises 40.7% but misses expectations
Brief: MaaT Pharma Says Xervyteg Under EMA Review, Decision Expected In H2 2026